Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Jun;32(6):890–895. doi: 10.1128/aac.32.6.890

Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes.

P R Wyde 1, H R Six 1, S Z Wilson 1, B E Gilbert 1, V Knight 1
PMCID: PMC172302  PMID: 2843086

Abstract

Enviroxime has been shown to inhibit the replication of rhinoviruses and other enteroviruses in concentrations as low as nanograms per milliliter in in vitro assays but is markedly less effective in clinical trials. The marked hydrophobicity and water insolubility of this compound may be a factor for this disparity. To overcome this handicap, we incorporated enviroxime into liposomes and then tested the antirhinovirus activity and toxicity of the liposome-incorporated enviroxime (LE) in cell culture and studied its administration by small-particle aerosol. Free enviroxime and LE were found to have equivalent efficacies against rhinovirus strains 1A and 13 in in vitro assays; however, preparations of LE were 10- to greater than or equal to 50-fold less toxic to tissue culture cells than was free enviroxime. In contrast to free enviroxime, which could not be delivered by small-particle aerosol because of its water insolubility, LE (4 mg/ml) was readily and successfully delivered by small-particle aerosol to the upper and lower respiratory tracts of mice; after just 20 min, significant levels of enviroxime were detected in the lungs and noses of exposed mice. Moreover, mice exposed to aerosols of liposomes containing both enviroxime and fluorescein isothiophosphatidylethanolamine showed accumulations of the fluorescent marker in the lungs, particularly in or around the tall columnar epithelial cells lining the bronchi and bronchioles.

Full text

PDF
890

Images in this article

893Image
on p.893

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alving C. R. Delivery of liposome-encapsulated drugs to macrophages. Pharmacol Ther. 1983;22(3):407–424. doi: 10.1016/0163-7258(83)90010-4. [DOI] [PubMed] [Google Scholar]
  2. DeLong D. C., Reed S. E. Inhibition of rhinovirus replication in in organ culture by a potential antiviral drug. J Infect Dis. 1980 Jan;141(1):87–91. doi: 10.1093/infdis/141.1.87. [DOI] [PubMed] [Google Scholar]
  3. Gregoriadis G., Ryman B. E. Lysosomal localization of -fructofuranosidase-containing liposomes injected into rats. Biochem J. 1972 Aug;129(1):123–133. doi: 10.1042/bj1290123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hall C. B., McBride J. T., Walsh E. E., Bell D. M., Gala C. L., Hildreth S., Ten Eyck L. G., Hall W. J. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med. 1983 Jun 16;308(24):1443–1447. doi: 10.1056/NEJM198306163082403. [DOI] [PubMed] [Google Scholar]
  5. Hayden F. G., Gwaltney J. M., Jr Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection. Antimicrob Agents Chemother. 1982 Jun;21(6):892–897. doi: 10.1128/aac.21.6.892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kende M., Alving C. R., Rill W. L., Swartz G. M., Jr, Canonico P. G. Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice. Antimicrob Agents Chemother. 1985 Jun;27(6):903–907. doi: 10.1128/aac.27.6.903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Knight V., McClung H. W., Wilson S. Z., Waters B. K., Quarles J. M., Cameron R. W., Greggs S. E., Zerwas J. M., Couch R. B. Ribavirin small-particle aerosol treatment of influenza. Lancet. 1981 Oct 31;2(8253):945–949. doi: 10.1016/s0140-6736(81)91152-1. [DOI] [PubMed] [Google Scholar]
  8. Koff W. C., Showalter S. D., Seniff D. A., Hampar B. Lysis of herpesvirus-infected cells by macrophages activated with free or liposome-encapsulated lymphokine produced by a murine T cell hybridoma. Infect Immun. 1983 Dec;42(3):1067–1072. doi: 10.1128/iai.42.3.1067-1072.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Levandowski R. A., Pachucki C. T., Rubenis M., Jackson G. G. Topical enviroxime against rhinovirus infection. Antimicrob Agents Chemother. 1982 Dec;22(6):1004–1007. doi: 10.1128/aac.22.6.1004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lopez-Berestein G., Hopfer R. L., Mehta R., Mehta K., Hersh E. M., Juliano R. L. Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. J Infect Dis. 1984 Aug;150(2):278–283. doi: 10.1093/infdis/150.2.278. [DOI] [PubMed] [Google Scholar]
  11. Lopez-Berestein G., Mehta R., Hopfer R. L., Mills K., Kasi L., Mehta K., Fainstein V., Luna M., Hersh E. M., Juliano R. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis. 1983 May;147(5):939–945. doi: 10.1093/infdis/147.5.939. [DOI] [PubMed] [Google Scholar]
  12. Lopez-Berestein G., Rosenblum M. G., Mehta R. Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. Cancer Drug Deliv. 1984 Summer;1(3):199–205. doi: 10.1089/cdd.1984.1.199. [DOI] [PubMed] [Google Scholar]
  13. McClung H. W., Knight V., Gilbert B. E., Wilson S. Z., Quarles J. M., Divine G. W. Ribavirin aerosol treatment of influenza B virus infection. JAMA. 1983 May 20;249(19):2671–2674. [PubMed] [Google Scholar]
  14. McIntosh K., Kurachek S. C., Cairns L. M., Burns J. C., Goodspeed B. Treatment of respiratory viral infection in an immunodeficient infant with ribavirin aerosol. Am J Dis Child. 1984 Mar;138(3):305–308. doi: 10.1001/archpedi.1984.02140410083024. [DOI] [PubMed] [Google Scholar]
  15. Mehta R., Lopez-Berestein G., Hopfer R., Mills K., Juliano R. L. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta. 1984 Mar 14;770(2):230–234. doi: 10.1016/0005-2736(84)90135-4. [DOI] [PubMed] [Google Scholar]
  16. Miller F. D., Monto A. S., DeLong D. C., Exelby A., Bryan E. R., Srivastava S. Controlled trial of enviroxime against natural rhinovirus infections in a community. Antimicrob Agents Chemother. 1985 Jan;27(1):102–106. doi: 10.1128/aac.27.1.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ninomiya Y., Aoyama M., Umeda I., Suhara Y., Ishitsuka H. Comparative studies on the modes of action of the antirhinovirus agents Ro 09-0410, Ro 09-0179, RMI-15,731, 4',6-dichloroflavan, and enviroxime. Antimicrob Agents Chemother. 1985 Apr;27(4):595–599. doi: 10.1128/aac.27.4.595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Phillpotts R. J., Jones R. W., Delong D. C., Reed S. E., Wallace J., Tyrrell D. A. The activity of enviroxime against rhinovirus infection in man. Lancet. 1981 Jun 20;1(8234):1342–1344. doi: 10.1016/s0140-6736(81)92520-4. [DOI] [PubMed] [Google Scholar]
  19. Phillpotts R. J., Wallace J., Tyrrell D. A., Tagart V. B. Therapeutic activity of enviroxime against rhinovirus infection in volunteers. Antimicrob Agents Chemother. 1983 May;23(5):671–675. doi: 10.1128/aac.23.5.671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Taber L. H., Knight V., Gilbert B. E., McClung H. W., Wilson S. Z., Norton H. J., Thurson J. M., Gordon W. H., Atmar R. L., Schlaudt W. R. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics. 1983 Nov;72(5):613–618. [PubMed] [Google Scholar]
  21. Tadakuma T., Ikewaki N., Yasuda T., Tsutsumi M., Saito S., Saito K. Treatment of experimental salmonellosis in mice with streptomycin entrapped in liposomes. Antimicrob Agents Chemother. 1985 Jul;28(1):28–32. doi: 10.1128/aac.28.1.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Wilson S. Z., Gilbert B. E., Quarles J. M., Knight V., McClung H. W., Moore R. V., Couch R. B. Treatment of influenza A (H1N1) virus infection with ribavirin aerosol. Antimicrob Agents Chemother. 1984 Aug;26(2):200–203. doi: 10.1128/aac.26.2.200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Wilson S. Z., Knight V., Moore R., Larson E. W. Amantadine small-particle aerosol: generation and delivery to man. Proc Soc Exp Biol Med. 1979 Jul;161(3):350–354. doi: 10.3181/00379727-161-40551. [DOI] [PubMed] [Google Scholar]
  24. Wilson S. Z., Knight V., Wyde P. R., Drake S., Couch R. B. Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice. Antimicrob Agents Chemother. 1980 Apr;17(4):642–648. doi: 10.1128/aac.17.4.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Wyde P. R., Wilson S. Z., Sun C. S., Knight V. Interferon aerosol suppression of vesicular stomatitis virus replication in the lungs of infected mice. Antimicrob Agents Chemother. 1984 Oct;26(4):450–454. doi: 10.1128/aac.26.4.450. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES